- Home
- ZVIA vs IMUX Comparison
ZVIA vs IMUX Comparison
Compare ZVIA & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVIA
- IMUX
- Stock Information
- Founded
- ZVIA 2007
- IMUX 2016
- Country
- ZVIA United States
- IMUX United States
- Employees
- ZVIA N/A
- IMUX N/A
- Industry
- ZVIA Beverages (Production/Distribution)
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- ZVIA Consumer Staples
- IMUX Health Care
- Exchange
- ZVIA Nasdaq
- IMUX Nasdaq
- Market Cap
- ZVIA 116.8M
- IMUX 100.0M
- IPO Year
- ZVIA 2021
- IMUX N/A
- Fundamental
- Price
- ZVIA $3.81
- IMUX $1.05
- Analyst Decision
- ZVIA Hold
- IMUX Strong Buy
- Analyst Count
- ZVIA 4
- IMUX 6
- Target Price
- ZVIA $1.56
- IMUX $12.67
- AVG Volume (30 Days)
- ZVIA 823.2K
- IMUX 798.9K
- Earning Date
- ZVIA 02-25-2025
- IMUX 02-20-2025
- Dividend Yield
- ZVIA N/A
- IMUX N/A
- EPS Growth
- ZVIA N/A
- IMUX N/A
- EPS
- ZVIA N/A
- IMUX N/A
- Revenue
- ZVIA $153,385,000.00
- IMUX N/A
- Revenue This Year
- ZVIA N/A
- IMUX N/A
- Revenue Next Year
- ZVIA $7.64
- IMUX N/A
- P/E Ratio
- ZVIA N/A
- IMUX N/A
- Revenue Growth
- ZVIA N/A
- IMUX N/A
- 52 Week Low
- ZVIA $0.62
- IMUX $0.97
- 52 Week High
- ZVIA $3.98
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- ZVIA 74.07
- IMUX 40.69
- Support Level
- ZVIA $2.98
- IMUX $1.00
- Resistance Level
- ZVIA $3.30
- IMUX $1.10
- Average True Range (ATR)
- ZVIA 0.35
- IMUX 0.07
- MACD
- ZVIA 0.00
- IMUX -0.01
- Stochastic Oscillator
- ZVIA 87.34
- IMUX 14.29
About ZVIA Zevia PBC
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.